Solan Headlines

DelveInsight Evaluates a Robust Adrenocortical Carcinoma Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain

 Breaking News
  • No posts were found

DelveInsight Evaluates a Robust Adrenocortical Carcinoma Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain

March 15
11:00 2023
DelveInsight Evaluates a Robust Adrenocortical Carcinoma Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain

DelveInsight’s, “Adrenocortical Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including Adrenocortical Carcinoma clinical trials and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


For Adrenocortical Carcinoma Emerging drugs, the Adrenocortical Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Adrenocortical Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.


In the Adrenocortical Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Adrenocortical Carcinoma clinical trials studies, Adrenocortical Carcinoma NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Key takeaways from the Adrenocortical Carcinoma Pipeline Report


  • DelveInsight’s Adrenocortical Carcinoma pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.


  • The leading Adrenocortical Carcinoma Companies include Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others.


  • Promising Adrenocortical Carcinoma Pipeline Therapies include OSI-906, ATR-101, Pembrolizumab, Sunitinib, TKM-080301, Axitinib, Iressa (ZD1839), Osilodrostat, and others.


  • The Adrenocortical Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The Adrenocortical Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.


Request a sample and discover the recent breakthroughs happening in the Adrenocortical Carcinoma Pipeline landscape @ Adrenocortical Carcinoma Pipeline Outlook Report


Adrenocortical Carcinoma Overview

Adrenal cortical carcinoma (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play an important role in the endocrine system, which is the system that produces and regulates hormones. ACC is also known as adrenocortical carcinoma. The adrenal cortex makes hormones that regulate metabolism and blood pressure. It also produces cortisol and the male hormones called androgens, such as testosterone. ACC may trigger excessive production of these hormones.


Adrenocortical Carcinoma Emerging Drugs Profile


  • Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer.


  • Ipilimumab: Bristol-Myers Squibb

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of Adrenocortical carcinoma.


For further information, refer to the detailed Adrenocortical Carcinoma Drugs Launch, Adrenocortical Carcinoma Developmental Activities, and Adrenocortical Carcinoma News, click here for Adrenocortical Carcinoma Ongoing Clinical Trial Analysis


Adrenocortical Carcinoma Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Adrenocortical Carcinoma. The companies which have their Adrenocortical Carcinoma drug candidates in the mid to advanced stage, i.e. phase II include, Bristol-Myers Squibb.


Adrenocortical Carcinoma Pipeline:


  • Late-stage products (phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular


Molecule Type

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type


Find out more about the Adrenocortical Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Adrenocortical Carcinoma Emerging Drugs @ Adrenocortical Carcinoma Treatment Landscape


Scope of the Adrenocortical Carcinoma Pipeline Report


  • Coverage- Global


  • Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others.


  • Adrenocortical Carcinoma Pipeline Therapies- OSI-906, ATR-101, Pembrolizumab, Sunitinib, TKM-080301, Axitinib, Iressa (ZD1839), Osilodrostat, and others.


  • Adrenocortical Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration


Dive deep into rich insights for drugs for Adrenocortical Carcinoma Pipeline Companies and Therapies, click here @ Adrenocortical Carcinoma Unmet Needs and Analyst Views


Table of Content

  1. Introduction
  2. Executive Summary
  3. Adrenocortical Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Adrenocortical Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Adrenocortical Carcinoma Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. Ipilimumab: Bristol-Myers Squibb
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. Relacorilant: Corcept Therapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Adrenocortical Carcinoma Key Companies
  17. Adrenocortical Carcinoma Key Products
  18. Adrenocortical Carcinoma- Unmet Needs
  19. Adrenocortical Carcinoma- Market Drivers and Barriers
  20. Adrenocortical Carcinoma- Future Perspectives and Conclusion
  21. Adrenocortical Carcinoma Analyst Views
  22. Adrenocortical Carcinoma Key Companies
  23. Appendix


Got Queries? Find out the related information on Adrenocortical Carcinoma Mergers and acquisitions, Adrenocortical Carcinoma Licensing Activities @ Adrenocortical Carcinoma Recent Trends, and Future Perspectives


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States